Necrotizing Enterocolitis
Conditions
Brief summary
The study will assess the efficacy of Docosahexaenoic Acid in reducing the incidence of necrotizing enterocolitis in premature infants.
Detailed description
The efficacy of Docosahexaenoic Acid in reducing the incidence of necrotizing enterocolitis in preterm neonates will be evalutaed through measuring its immune-modulatory effect on proinflammatory cytokines.
Interventions
DIETARY_SUPPLEMENTDocosahexaenoic Acid
100 milligrams of Docosahexaenoic Acid
OTHERplacebo
placebo
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Days to 3 Weeks
Healthy volunteers
No
Inclusion criteria
* Preterm neonates having a gestational age equal or less than 34 weeks at birth. * Weight (less than or equal 1.500 KG) * Clinically stable to begin enteral feeding
Exclusion criteria
* Persistent bleeding at any level. * Receiving medication to avoid coagulation. * Persistent vomiting. * Gastrointestinal malformations. * Mother taking Omega-3 supplements and planning to breastfeed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of Docosahexaenoic Acid in reducing the incidence of Necrotizing Enterocolitis in premature infants. | 10 days | Monitoring the change in the serum levels of Interleukin-1 beta |
Contacts
Primary ContactDina Abou El Fadl, Msc.
Backup ContactYasmine Farid, MD
Outcome results
None listed